Spiro-isoxazolidine derivatives as cholinergic agents
US5073560A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jul 20, 1990 |
| Grant date | Dec 17, 1991 |
| Priority date | — |
| Expiry date | Jul 20, 2010 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/20
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of general formula I, ##STR1## wherein: A represents (CH.sub.2).sub.m optionally substituted by R.sub.3, PA1 B represents (CH.sub.2).sub.n optionally substituted by R.sub.4, PA1 R.sub.1 represents hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1-6 alkenyl or C.sub.1-6 alkynyl, PA1 R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 alkyl or COOR.sub.5, in which R.sub.5 represents C.sub.1 -C.sub.6 alkyl, PA1 R.sub.3 and R.sub.4 independently represent hydrogen or C.sub.1 -C.sub.6 alkyl, PA1 in addition, any two of R.sub.2, R.sub.3 and R.sub.4 may together form a C.sub.1-3 alkylene chain, PA1 n and m independently represent an integer from 1-3 inclusive, PA1 Y represents O or S, PA1 and pharmaceutically acceptable acid addition salts thereof are useful as pharmaceuticals, in particular as central muscarinic acetylcholine receptor agonists. The compounds are therefore useful in the treatment of diseases such as presenile and senile dementia, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania and Tourette Syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.